AI assistant
Sending…
EyePoint Pharmaceuticals, Inc. — Director's Dealing 2020
Jun 16, 2020
32254_dirs_2020-06-16_875bc430-cdf3-49f4-8491-7a91d7c48b3f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: EyePoint Pharmaceuticals, Inc. (EYPT)
CIK: 0001314102
Period of Report: 2020-06-14
Reporting Person: Lurker Nancy (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-06-14 | Common Stock | M | 45000.00 | $0.00 | Acquired | 619800.00 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2020-06-14 | Restricted Stock Units | $0.00 | M | 45000.00 | Disposed | Common Stock (45000.00) | Direct |
Footnotes
F1: On June 14, 2018, the reporting person was granted 135,000 restricted stock units, vesting in three equal annual installments beginning on the first anniversary of the grant date.
More from EyePoint Pharmaceuticals, Inc.
Regulatory Filings
2026
May 14
Regulatory Filings
2026
May 6
Regulatory Filings
2026
Apr 13
Director's Dealing
2026
Mar 24
Regulatory Filings
2026
Mar 20
Regulatory Filings
2026
Mar 4
Regulatory Filings
2026
Mar 2
Director's Dealing
2026
Feb 18
Major Shareholding Notification
2026
Feb 12
Director's Dealing
2026
Jan 7